Adlai Nortye Ltd. American Depositary Shares (ANL)

About ANL

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibi…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

109

Website

www.adlainortye.com

Fundamentals

1-day range

$14.6$15.2

Market cap

$946.44M

P/E (trailing)

—

P/E (forward)

-51.00

EPS (trailing)

$-0.66

Dividend yield

—

Beta

1.12

Avg. volume

178.2K

Forecasts

5 analyst ratings

Adlai Nortye Ltd. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• ANL

  Adlai Nortye Ltd. American Depositary Shares

  $13.82

  ▼ 3.49%
  Market cap $946.44MP/E —
  $0.879$17.25
• JANX

  Janux Therapeutics Inc. Common Stock

  $18.01

  ▼ 4.10%
  Market cap $934.28MP/E —
  $12.12$35.34
• OMER

  Omeros Corporation Common Stock

  $18.59

  ▼ 3.43%
  Market cap $909.03MP/E 14.37
  $3.94$19.65
• OLMA

  Olema Pharmaceuticals Inc. Common Stock

  $10.28

  ▼ 4.77%
  Market cap $985.28MP/E —
  $5.36$36.26
• AMPH

  Amphastar Pharmaceuticals Inc. Common Stock

  $22.01

  ▲ 0.59%
  Market cap $891.56MP/E 10.93
  $16.65$31.26
• IVA

  Inventiva S.A. American Depository Shares

  $4.71

  ▼ 3.98%
  Market cap $1.00BP/E —
  $2.88$6.2
• ANNX

  Annexon Inc. Common Stock

  $4.97

  ▼ 5.33%
  Market cap $860.17MP/E —
  $2.03$7.18

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

11.59M

Total value held

$79.49M

Institutional holders

26